<DOC>
	<DOCNO>NCT02521896</DOCNO>
	<brief_summary>The study intend assess safety performance Vadoâ„¢ Steerable Sheath facilitate ease access pulmonary vein ( PV ) treatment paroxysmal atrial fibrillation persistent atrial fibrillation ( AF ) . The study prospective , single-center , non-randomized investigation .</brief_summary>
	<brief_title>Safety Performance Study Evaluate Access Pulmonary Veins Treatment Paroxysmal AF</brief_title>
	<detailed_description>The design study involve sequential enrollment patient document paroxysmal atrial fibrillation two ( 2 ) AF episodes least 30 second length within six ( 6 ) month prior enrollment . Target population shall select treatable AF population meet inclusion/exclusion criteria.It intend Vado Steerable Sheath use part standard clinical workflow procedure , procedural deviation relative procedure require steerable sheath . Individual subject study map ablation procedure follow release hospital post procedure per institutional standard care .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>suitable candidate intracardiac mapping arrhythmia document PAF define HRS Criteria . Eighteen Eighty year age Signed informed consent Intracardiac thrombus , tumor abnormality precludes catheter introduction placement Severe cerebrovascular disease history cerebrovascular event within one ( 1 ) month Patients severely impaired kidney function measure CockcroftGault Glomerular Filtration Rate ( GFR ) 3 GFR &lt; 29 . Active gastrointestinal bleeding , infection fever ( &gt; 100.5/38C ) Severe co morbidity Short life expectancy ( &lt; 1 year ) due illness cancer , pulmonary , hepatic renal disease Structural heart disease clinical significance include Symptoms congestive heart failure include , limited , NYHA Class III IV CHF and/or document ejection fraction &lt; 40 % measure acceptable cardiac test Stable/unstable angina ongoing myocardial ischemia Myocardial infarction ( MI ) within three month enrollment Aortic mitral valve disease &gt; Grade II Congenital heart disease ( include ASD PFO without right left shunt ) underlie abnormality increase risk ablative procedure Enrollment ongoing arrhythmia study protocol Any ventricular tachyarrhythmia currently treat arrhythmia management may interfere study Active infection sepsis Female patient pregnant lactate Untreatable allergy contrast medium Any diagnosis atrial fibrillation secondary electrolyte imbalance , thyroid disease , reversible noncardiovascular cause History blood clotting ( bleed thrombotic ) abnormalities Known sensitivity heparin warfarin Severe COPD ( identify FEV1 &lt; 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>